Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis-Reference-Cited by-同舟云学术

Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis

Published:2023-11-20 Issue: Volume: Page:
ISSN:1559-0100
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Wong Chun Ho,Kan Andy Ka Chun,Tsoi Kimberly Hang,Chan Stacey Sheung Yi,Jiang Nancy Su,Loong Connie Hong Nin,Fong Carol Ho Yi,Wong Janus Siu Him,Shea Graham Ka Hon,Cheung Ching Lung,Lee Chi Ho,Tan Kathryn Choon Beng,Woo Yu Cho,Lui David Tak Wai^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s12020-023-03608-z.pdf

Reference42 articles.

1. T.P. Ip, S.K. Cheung, T.C. Cheung et al. The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med. J. 19, 1–40 (2013)

2. S. Silverman, E. Kupperman, S. Bukata, Bisphosphonate-related atypical femoral fracture: managing a rare but serious complication. Cleve Clin. J. Med. 85, 885–893 (2018). https://doi.org/10.3949/ccjm.85a.17119

3. D.M. Black, E.J. Geiger, R. Eastell et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N. Engl. J. Med. 383, 743–753 (2020). https://doi.org/10.1056/NEJMoa1916525

4. J. Starr, Y.K.D. Tay, E. Shane, Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr. Osteoporos. Rep. 16, 519–529 (2018). https://doi.org/10.1007/s11914-018-0464-6

5. M.J. Bégin, M.C. Audet, T. Chevalley et al. Fracture risk following an atypical femoral fracture. J. Bone Miner. Res. 37, 87–94 (2022). https://doi.org/10.1002/jbmr.4461